Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1

ABSTRACT The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) complex comprises three gp120 exterior glycoproteins each noncovalently linked to a gp41 transmembrane glycoprotein. Monomeric gp120 proteins can elicit antibodies capable of neutralizing atypically sensitive test viruses in vitro, but these antibodies are ineffective against representative primary isolates and the gp120 vaccines failed to provide protection against HIV-1 transmission in vivo. Alternative approaches to raising neutralizing antibodies are therefore being pursued. Here we report on the antibody responses generated in rabbits against a soluble, cleaved, trimeric form of HIV-1JR-FL Env. In this construct, the gp120 and gp41 moieties are covalently linked by an intermolecular disulfide bond (SOS gp140), and an I559P substitution has been added to stabilize gp41-gp41 interactions (SOSIP gp140). We investigated the value of DNA priming and compared the use of membrane-bound and soluble priming antigens and of repeat boosting with soluble and particulate protein antigen. Compared to monomeric gp120, SOSIP gp140 trimers elicited approximately threefold lower titers of anti-gp120 antibodies. Priming with DNA encoding a membrane-bound form of the SOS gp140 protein, followed by several immunizations with soluble SOSIP gp140 trimers, resulted in antibodies capable of neutralizing sensitive strains at high titers. A subset of these sera also neutralized, at lower titers, HIV-1JR-FL and some other primary isolates in pseudovirus and/or whole-virus assays. Neutralization of these viruses was immunoglobulin mediated and was predominantly caused by antibodies to gp120 epitopes, but not the V3 region.

[1]  Brian Seed,et al.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.

[2]  S. A. Gallo,et al.  The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.

[3]  D. Montefiori,et al.  Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization , 2002, Journal of Virology.

[4]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[5]  R. Compans,et al.  Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. , 2004, Virology.

[6]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[7]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[8]  R. Desrosiers,et al.  Viral persistence: HIV's strategies of immune system evasion. , 2002, Annual review of medicine.

[9]  J. Moore,et al.  Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion , 2003, Journal of Virology.

[10]  B. Korber,et al.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.

[11]  A. McMichael,et al.  DNA vaccines against human immunodeficiency virus type 1 , 2004, Immunological reviews.

[12]  E. Hunter,et al.  Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation , 1995, Journal of virology.

[13]  Bette T. Korber,et al.  Immune control of HIV: the obstacles of HLA and viral diversity , 2001, Nature Immunology.

[14]  J. Haas,et al.  Identification of Two Sequences in the Cytoplasmic Tail of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein That Inhibit Cell Surface Expression , 2001, Journal of Virology.

[15]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  I. Mathiesen Electropermeabilization of skeletal muscle enhances gene transfer in vivo , 1999, Gene Therapy.

[17]  John P. Moore,et al.  Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.

[18]  S. Harrison,et al.  A Chimeric Protein of Simian Immunodeficiency Virus Envelope Glycoprotein gp140 and Escherichia coli Aspartate Transcarbamoylase , 2004, Journal of Virology.

[19]  B. Graham Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[20]  J. Bonifacino,et al.  A Membrane-proximal Tyrosine-based Signal Mediates Internalization of the HIV-1 Envelope Glycoprotein via Interaction with the AP-2 Clathrin Adaptor* , 1998, The Journal of Biological Chemistry.

[21]  D R Burton,et al.  gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.

[22]  J. Sodroski,et al.  Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. , 2003, AIDS research and human retroviruses.

[23]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[24]  J. Ulmer,et al.  Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo , 2000, The Journal of Immunology.

[25]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[26]  Q. Sattentau,et al.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.

[27]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[28]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[29]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[30]  Gary J. Nabel,et al.  The need for a global HIV vaccine enterprise. Policy forum. , 2003 .

[31]  L. Stamatatos,et al.  Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus , 2002, Journal of Virology.

[32]  A. McMichael,et al.  Prospects for an AIDS vaccine. , 2003, Clinical medicine.

[33]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[34]  Richard D. Leapman,et al.  Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface , 2002, Journal of Virology.

[35]  Q. Sattentau,et al.  Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. , 2004, Vaccine.

[36]  Min Lu,et al.  Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.

[37]  D. Weiner,et al.  DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade , 2004, Clinical Microbiology Reviews.

[38]  A. Trkola,et al.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.

[39]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[40]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[41]  J. Sodroski,et al.  Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. , 2004, Virology.

[42]  Q. Sattentau,et al.  Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design". , 1997, Immunology letters.

[43]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[44]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[45]  J. Bonifacino,et al.  Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. , 1997, Virology.

[46]  J. Binley,et al.  Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2002, Journal of Virology.

[47]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[48]  S. Zolla-Pazner,et al.  Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[49]  J. Sodroski,et al.  Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.

[50]  Guillaume Blot,et al.  The Highly Conserved C-Terminal Dileucine Motif in the Cytosolic Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Is Critical for Its Association with the AP-1 Clathrin Adapter , 2001, Journal of Virology.

[51]  John P. Moore,et al.  Urgently needed: a filter for the HIV-1 vaccine pipeline , 2004, Nature Medicine.

[52]  D. Burton,et al.  gp41: HIV's shy protein , 2004, Nature Medicine.

[53]  Q. Sattentau,et al.  Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. , 1997, Immunology letters.

[54]  A. Trkola,et al.  Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[55]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[56]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[57]  A. Trkola,et al.  Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.

[58]  J. Mascola,et al.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 , 1997, Journal of virology.

[59]  J. Binley,et al.  Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions , 2003, Journal of Virology.

[60]  J. Mascola,et al.  The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.

[61]  Yiming Shao,et al.  Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.

[62]  Jon Cohen,et al.  Public health. AIDS vaccine trial produces disappointment and confusion. , 2003, Science.

[63]  C. Barbas,et al.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.

[64]  M. Feinberg,et al.  Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.

[65]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[66]  A. McMichael,et al.  HIV vaccines 1983–2003 , 2003, Nature Medicine.

[67]  B. Moss,et al.  Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras , 2004, Journal of Virology.

[68]  E. Freed,et al.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Moore,et al.  Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. , 1994, Journal of acquired immune deficiency syndromes.

[70]  New hope for AIDS vaccine. , 2003, Lancet.

[71]  John P. Moore,et al.  Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development , 2001, Journal of Virology.

[72]  P. Doherty,et al.  Limited Breadth of a T-Helper Cell Response to a Human Immunodeficiency Virus Envelope Protein , 2003, Journal of Virology.

[73]  L. Stamatatos,et al.  Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.

[74]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[75]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[76]  D. Ho,et al.  Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection , 1996, Journal of virology.

[77]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[78]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Sodroski,et al.  Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.

[80]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[81]  R. Compans,et al.  Surface Stability and Immunogenicity of the Human Immunodeficiency Virus Envelope Glycoprotein: Role of the Cytoplasmic Domain , 2004, Journal of Virology.

[82]  P. Doherty,et al.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing , 2001, Proceedings of the National Academy of Sciences of the United States of America.